Skip to main content
Premium Trial:

Request an Annual Quote

EGEN microRNA Inhibitor Shows Promise in Preclinical Testing

Premium

EGEN announced this week that its microRNA inhibitor-based treatment for pulmonary arterial hypertension was able to reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function in rat models.

According to the company, the drug targets miR-145, which has been linked to vascular remodeling in PAH, and is delivered with a propriatry mPEG nanoparticle that is administered directly to the lung.

EGEN is also developing RNAi-based drugs with a focus on cancer (GSN 8/5/2010).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.